- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of June 11
The Center for Biosimilars® recaps the top 5 articles for the week of June 11, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 11.
Number 5: HHS Secretary Alex Azar testified before the Senate Committee on Health, Education, Labor, and Pensions on the Trump administration’s blueprint to lower drug prices, but The American College of Rheumatology is raising concerns about some of HHS’s proposals.
Number 4: The FDA has announced the publication of 2 final guidance documents that seek to provide greater clarity on medical product communications.
Number 3: Research presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, in Amsterdam, Netherlands, finds that, once patients are educated about biosimilars, most are willing to switch.
Number 2: The Senate Judiciary Committee voted 16 to 5 to report the CREATES Act to the Senate floor.
Number 1: Walgreen and Kroger have filed an antitrust suit against Johnson & Johnson and Janssen, alleging unlawful exclusion of biosimilar competition for infliximab.
Finally, last week, our e-newsletter asked whether the FDA’s approval of Fulphila will improve patient access to prophylaxis of febrile neutropenia.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
